Cervical cancer incidence higher in states with lower proportion of HPV vaccination rates
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of North Carolina Gillings School of Global Public Health in Chapel Hill, North Carolina, the number of adolescent girls receiving the human papillomavirus (HPV) vaccine is much lower in states with higher rates of cervical cancer and cervical cancer-related mortality.
Using the National Immunization Survey-Teen, researchers identified the rates of HPV vaccination in various states, and identified cervical cancer rates in the same states using the United States Cancer Statistics database. States with higher vaccination rates had lower cancer incidence rates and vice versa.
For example, in Massachusetts, 69% of adolescent girls have begun the HPV vaccination series and 6 per 100,000 women develop cervical cancer a year, whereas in Arkansas, 41% of adolescent girls have initiated HPV vaccination and 10 per 100,000 women develop cervical cancer a year. In addition, completion rates of the HPV vaccine course were higher in states where adolescents have higher levels of contact with the healthcare system.
The researchers suggest that more adolescent preventive health care may be needed to improve completion rates of the HPV vaccination series.
Number of adolescent girls receiving the HPV vaccine much lower in states with higher rates of cervical cancer.
The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
HPV vaccines can prevent individuals from developing several types of cancer, including cervical, anal, vaginal, and vulvar cancers. "Cervical cancer incidence and mortality rates vary widely by state," said Jennifer L. Moss, MSPH, a doctoral student in the Department of Health Behavior at the University of North Carolina Gillings School of Global Public Health in Chapel Hill.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|